Boltz raises $110 million to build AI models for drug design

Nov 19, 2026
Bessemer led the Series A for the London-based MIT spinout, which works with Pfizer, GSK, Takeda and Bristol Myers Squibb.

London-based AI drug discovery startup Boltz has raised a $110 million Series A, less than a year after coming out of stealth with a $28 million seed round. Bessemer Venture Partners led the round, joined by existing investors including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures. New backers include Greycroft, F-Prime Capital, Hummingbird and Benchling, alongside Nvidia, which announced an investment earlier this year.

Boltz builds models that help pharmaceutical and biotech researchers design potential drugs and choose which candidates to test in the lab. Its models predict how a protein and a drug candidate look when bound together, estimate how strongly they bind, and propose new molecules designed for a target. Its co-founders released open-source models at MIT that matched the performance of closed models such as DeepMind's AlphaFold3.

The company, spun out of MIT and now employing 40 AI researchers in London's King's Cross, has announced collaborations with Pfizer, GSK, Takeda and Bristol Myers Squibb. It earns money from partnerships and from access to its platform and custom models. In its own announcement, Boltz says it has signed partnerships with six of the world's 20 largest pharma companies and that molecular token usage among paying customers has grown 50-fold since June, when it released its first proprietary models, BoltzMol-1 and BoltzProt-1.

"Our upcoming models are already showing substantial improvements in the quality of the molecules they generate," the company said, adding that its goal requires substantial investment in compute and data, according to Tech.eu.

We hope you enjoyed this article

Free newsletter

AI in Europe

Daily AI news from Europe, chosen by Rene van Pelt: European companies, the EU and the UK, chips and data centres, deals and regulation, in a few minutes.

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.